Patients with mCRPC prostate cancer have an elevated risk of fractures due to bone metastases and use of androgen receptor pathway inhibitors (ARPI).
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback